Scholarlink

<p>Esophageal barrier has been investigated until now on the epithelial side only. Gut vascular barrier dysfunction has been recently implicated in a number of immune-mediated gastrointestinal disorders. We here characterized the esophageal vascular barrier (EVB) in eosinophilic esophagitis (EoE). Probe-based confocal laser endomicroscopy (pCLE) was performed in two EoE and two reflux esophagitis (RE) patients. The vascular barrier marker plasmalemma vesicle-1 (PV-1) was investigated as a measure of barrier disruption, by both immunohistochemistry and qPCR, in esophageal biopsies of 16 patients with EoE, 15 with RE, and 15 healthy controls (HC). In EoE, but not RE, pCLE revealed leakage of the EVB, which was restored in one patient after dupilumab treatment. PV-1 was significantly increased in EoE in comparison to RE and HC, both in terms of protein and transcript levels, supporting vascular leakage. EVB is disrupted in active EoE. Further studies are needed to understand the diagnostic and pathogenic implications of this finding.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disrupted mucosal vascular barrier in eosinophilic esophagitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Marco Vincenzo Lenti,
  • Carlo Maria Rossi,
  • Renato Cannizzaro,
  • Giovanni Santacroce,
  • Michela Lizier,
  • Giulia Fornasa,
  • Stefania Merli,
  • Alessandra Pasini,
  • Edoardo Vincenzo Savarino,
  • Paola Spessotto,
  • Michele Di Stefano,
  • Aurelio Mauro,
  • Alessandro Vanoli,
  • Fabiana Zingone,
  • Andrea Anderloni,
  • Marietta Iacucci,
  • Maria Rescigno,
  • Antonio Di Sabatino

摘要

Esophageal barrier has been investigated until now on the epithelial side only. Gut vascular barrier dysfunction has been recently implicated in a number of immune-mediated gastrointestinal disorders. We here characterized the esophageal vascular barrier (EVB) in eosinophilic esophagitis (EoE). Probe-based confocal laser endomicroscopy (pCLE) was performed in two EoE and two reflux esophagitis (RE) patients. The vascular barrier marker plasmalemma vesicle-1 (PV-1) was investigated as a measure of barrier disruption, by both immunohistochemistry and qPCR, in esophageal biopsies of 16 patients with EoE, 15 with RE, and 15 healthy controls (HC). In EoE, but not RE, pCLE revealed leakage of the EVB, which was restored in one patient after dupilumab treatment. PV-1 was significantly increased in EoE in comparison to RE and HC, both in terms of protein and transcript levels, supporting vascular leakage. EVB is disrupted in active EoE. Further studies are needed to understand the diagnostic and pathogenic implications of this finding.